Orforglipron Met Cardiovascular Safety Benchmarks
The Phase 3 ACHIEVE-4 trial showed orforglipron is noninferior to insulin glargine for cardiovascular risk.
Updated on Oct. 5, 2026 in Diabetes
Live Poll
Would you prefer using new oral medications over traditional insulin for managing your diabetes treatment?
The Phase 3 ACHIEVE-4 trial has demonstrated that the oral drug orforglipron is noninferior to insulin glargine regarding major adverse cardiovascular events in adults with type 2 diabetes. Findings indicate the medication also outperformed insulin glargine in reducing HbA1C levels and body weight.
Why it matters
This study was conducted to confirm that orforglipron does not increase cardiovascular risk for patients managing type 2 diabetes. The results provide clinical evidence for the drug's safety profile when compared to standard insulin therapy.
In the trial of 2,749 adults, orforglipron reduced HbA1C by 0.50 percentage points and body weight by 8.9% more than insulin glargine at week 52. These figures are compared against the insulin glargine control group.
The players
ACHIEVE-4
This is a large-scale Phase 3 clinical trial designed to evaluate the safety and efficacy of orforglipron compared to insulin glargine.
The Lancet
This is a prominent peer-reviewed medical journal that published the results of the ACHIEVE-4 study.
The details
Participants took daily oral orforglipron, escalated to a 36 mg capsule, or used titrated insulin glargine to manage diabetes. While orforglipron showed lower rates of hypoglycemia at 6.8% compared to 19.2% for insulin, it also resulted in higher gastrointestinal adverse events at 62.1% and a 15.4% discontinuation rate.
Timeline
April 2026: Orforglipron received FDA approval for chronic weight management.
Week 52: Researchers measured HbA1C and weight reduction outcomes.
Week 104: The study reached its median follow-up period.
September 30, 2026: ACHIEVE-4 trial results were published in The Lancet.
The Big Picture
This research follows the safety protocols established by the ATTAIN-Outcomes study. The current results extend this framework by providing the necessary cardiovascular safety data required before long-term risk reduction can be confirmed.
Patients may find that orforglipron offers a weight-reduction and glycemic-control alternative to injectable insulin glargine with a lower risk of hypoglycemia. However, users should be aware that gastrointestinal side effects are significantly more common with this oral treatment.
The takeaway
Orforglipron represents a significant shift in diabetes care by offering an oral alternative to traditional insulin therapy with distinct efficacy and side-effect profiles. Patients and providers should weigh the benefits of reduced hypoglycemia and improved weight management against the higher rate of gastrointestinal adverse events.
What happens next
The ongoing ATTAIN-Outcomes study will eventually report findings on whether orforglipron actively reduces the risk of cardiovascular events, with results expected upon completion of that specific trial.
Further reading
For additional context on current research and treatment advancements, visit the Diabetes section.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Would you prefer using new oral medications over traditional insulin for managing your diabetes treatment?
